The effect of famotidine on reducing the side effects of prostate cancer radiotherapy
Phase 3
Recruiting
- Conditions
- Prostate cancer.Malignant neoplasm of prostate
- Registration Number
- IRCT20231121060132N1
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Patients aged 30 to 75 with prostate cancer candidates for radiotherapy
Do not receive PPI drugs and other H2 antagonist drugs
Exclusion Criteria
Lack of consent to participate in the study
Patients with kidney disease that cannot be prescribed famotidine
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mucosal lesions. Timepoint: weekly. Method of measurement: Using the Visual Analogue Scale questionnaire.;Lymphocytopenia. Timepoint: weekly. Method of measurement: Blood cell count test.;Granulocytopenia. Timepoint: weekly. Method of measurement: Blood cell count test.;Thrombocytopenia. Timepoint: weekly. Method of measurement: Blood cell count test.;Anemia. Timepoint: weekly. Method of measurement: Blood cell count test.
- Secondary Outcome Measures
Name Time Method